CPI-4

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCPI-4
Drug Alias NameEP300/CBP histone acetyltransferase inhibitor (Constellation Pharmaceuticals)CPI-4
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone acetyltransferase p300 degraderscAMP-response element binding protein inhibitors
TargetscAMP-response element binding proteinHistone acetyltransferase p300
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesConstellation Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesConstellation Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A